US0956334009 - Common Stock
BLUEJAY DIAGNOSTICS INC
NASDAQ:BJDX (10/28/2024, 8:04:27 PM)
Premarket: 0.1047 0 (-1.13%)0.1059
+0 (+0.57%)
Bluejay Diagnostics Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Acton, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2021-11-10. Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
BLUEJAY DIAGNOSTICS INC
360 Massachusetts Avenue, Suite 203
Acton MASSACHUSETTS
P: 19786310152
Employees: 10
Website: https://bluejaydx.com/
BJDX stock results show that Bluejay Diagnostics missed analyst estimates for earnings per share the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bluejay Diagnostics (NASDAQ:BJDX) just reported results for the second quarter ...
ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company...
ACTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company...
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning!
Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days...
Here you can normally see the latest stock twits on BJDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: